Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has been granted an additional 180-day period by Nasdaq to meet the minimum bid price requirement after failing to comply
Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has been granted an additional 180-day period by Nasdaq to meet the minimum bid price requirement after failing to comply
הפטנט הזה הוא עבור שימוש בתערובת של ארמכול ורסמטירום לטיפול ב-NASH/MASH וצלקות כבד. צרפת, גרמניה, איטליה, הולנד והממלכה המאוחדת כולם אישרו את הפטנט הזה. Galmed גם ממתינים לאישור של ארצות
Galmed Pharmaceuticals announced the grant of a European patent related to the use of a combination of Aramchol and Resmetirom for the treatment of NASH/MASH and liver fibrosis. The patent
Maxim analyst Jason McCarthy lowered the firm’s price target on Galmed to $1 from $4 but keeps a Buy rating on the shares. The analyst cites the company having announced
Galmed Pharmaceuticals announced a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis, or PSC, Ph 2a Study. In May Galmed announced the pivoting of